Contact Us
Drug Search Results
More Filters [+]

NBI-1070770

Alternative Names: NBI-1070770, NBI1070770, NBI 1070770
Latest Update: 2024-04-12
Latest Update Note: Clinical Trial Update

Product Description

Neurocrine is developing NBI-1070770 as a treatment for Major Depressive Disorder. (Sourced from: https://www.neurocrine.com/clinical-studies/)

Mechanisms of Action: NMDA NAM

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Neurocrine
Company Location: SAN DIEGO CA 92130
Company CEO: Kevin C. Gorman
Additonal Commercial Interests: Takeda

Clinical Description

Map of Global Clinical Trials for NBI-1070770

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Depressive Disorder, Major

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NBI-1070770-MDD2029

P2

Recruiting

Depressive Disorder, Major

2025-09-01

32%

Recent News Events

Date

Type

Title

04/03/2024

News Article

 Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions